Alaunos Therapeutics
TCRT
122 hedge funds and large institutions have $376M invested in Alaunos Therapeutics in 2017 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 44 increasing their positions, 31 reducing their positions, and 16 closing their positions.
42% more repeat investments, than reductions
Existing positions increased: 44 | Existing positions reduced: 31
11% more capital invested
Capital invested by funds: $337M → $376M (+$38.6M)
0.02% more ownership
Funds ownership: 0.27% → 0.28% (+0.02%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
2% less funds holding
Funds holding: 124 → 122 (-2)
13% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 16
36% less call options, than puts
Call options by funds: $7.22M | Put options by funds: $11.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$47.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.62M |
| 3 |
State Street
Boston,
Massachusetts
|
+$3.38M |
| 4 |
ARTA
A.R.T. Advisors
New York
|
+$1.97M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.79M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$6.66M |
| 2 |
Morgan Stanley
New York
|
-$3.67M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$2.82M |
| 4 |
California Public Employees Retirement System
Sacramento,
California
|
-$1.45M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$1.44M |
TCRT Hedge Fund Activity: Q2 2017 in Review
122 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q2 2017, worth a combined $376M — up 11% from $337M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of TCRT and 14 opened new positions — a net loss of 2 holders — while 31 trimmed existing stakes and 44 added.
The largest buyer was Susquehanna International Group, adding an estimated $47.8M. The largest seller was Invesco, exiting entirely with an estimated $6.66M sold.
- 122 institutional investors held Alaunos Therapeutics (TCRT) as of Q2 2017, down from 124 in Q1 2017.
- Funds reported $376M of Alaunos Therapeutics stock for Q2 2017, up 11% quarter-over-quarter.
- 14 funds opened new Alaunos Therapeutics positions in Q2 2017 and 16 closed out, a net change of -2 holders.
- The largest Alaunos Therapeutics buyer in Q2 2017 was Susquehanna International Group, an estimated $47.8M added.
- The largest Alaunos Therapeutics seller in Q2 2017 was Invesco, an estimated $6.66M sold.
Based on aggregated 13F filings for Q2 2017.